0.745
0.00 (0.00%)
| Previous Close | 0.745 |
| Open | 0.750 |
| Volume | 129,070 |
| Avg. Volume (3M) | 394,584 |
| Market Cap | 256,950,496 |
| Price / Earnings (Forward) | 40.32 |
| Price / Sales | 3.74 |
| Price / Book | 3.15 |
| 52 Weeks Range | |
| Earnings Date | 26 Nov 2024 |
| Profit Margin | -15.39% |
| Operating Margin (TTM) | -13.37% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | 9.30% |
| Total Debt/Equity (MRQ) | 7.83% |
| Current Ratio (MRQ) | 7.26 |
| Operating Cash Flow (TTM) | -7.38 M |
| Levered Free Cash Flow (TTM) | -11.84 M |
| Return on Assets (TTM) | -5.86% |
| Return on Equity (TTM) | -10.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (AU) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | AROA BIO FPO [ARX] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 26.29% |
| % Held by Institutions | 21.72% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |